Attend the FierceBiotech Executive Breakfast at BIO 2019
Join us on June 5th for our panel discussion on real-world evidence. Reserve your seat today.
Sandoz may have to wait a little longer for a clear shot at launching a biosimilar to Amgen's anti-inflammatory blockbuster Enbrel.
Allergan took all kinds of criticism for its tribal licensing deal, but an appeals court decision has breathed new life into the strategy.
Prove it, GSK. So says a judge in the Coreg "carve-out" patent case that last year ended in a $235 million judgment against generics maker Teva.
AbbVie scored a major reduction of damages in a retrial of an AndroGel liability case brought by plaintiff Jesse Mitchell.
Retailers settled claims that Impax made an illegal deal to delay its generic version of Solodyn, but insurer and consumer plaintiffs are fighting on.
Endo, Teva and a Japanese drugmaker have agreed to fork over more than $270 million to resolve a class-action suit over Lidoderm.
Federal prosecutors say they'll show Novartis traded fancy dinners—and in some cases, jobs for physicians' relatives—to boost prescription numbers.
Under a 2003 agreement, Array BioPharma says AstraZeneca needs to pony up $192 million.
The feds charged five doctors over accepting Insys' bribes and said they've secured cooperation from two former employees.
Three people injected with an unauthorized herpes vaccine by a Southern Illinois University researcher have filed suit against his company.